ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / LIVN / news
ITGR (67) AXGN (53) TMDX (61) CNMD (62) ⌘ Pro Terminal →

Why LIVN Stock advanced +1.57% Today — RQD Quant Desk Flash

$80.21 +1.57% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $80.28

LivaNova PLC (LIVN) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $4.35B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LIVN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LIVN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, LivaNova PLC (NASDAQ: LIVN) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 66/100 at a spot price of $80.21 (+1.57% 1D, market cap $4.35B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, LIVN ranks #111 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LIVN compare to ITGR and AXGN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), LIVN carries a Roarable C+ (66/100 RQD), trailing P/E of N/A, gross margin of 67.7%, and ROIC of 17.3%. By comparison, ITGR (Integer Holdings Corporation) holds a C+ grade (67/100 RQD, P/E 41.8x, ROIC 6.0%, cap $4.30B) and AXGN (Axogen Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC -2.6%, cap $2.95B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LIVN?
▼

Per LIVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001639691), LivaNova PLC generated $1.39B in revenue (+10.7% YoY), -$242.5M in net income, and $173.3M in free cash flow against $2.61B in total assets and $345.2M in total debt. Key quantitative strengths: Strong cash generator (67.7% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $80.28 (+0.09%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 12.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 66/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.4% avg 90D alpha vs SPY • 56.0% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C+
025507510066
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw C+ · Rk C
Cash (16)Whales (13)SEC (12)Macro (13)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE+3.6% Base Target
$98 Bull$83 Base$65 Bear
📬 FREE LIVN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LIVN)Realized 20D OHLCV Swing Band: ±5.7%
Deterministic 5-Pillar Attribution (66/100 Composite)
🔍 WHY LIVN SCORES 66/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 12.5% FCF Margin ($173.3M FCF) & 67.7% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+13/20 pts (20% of score)

20D Institutional Volume Accumulation (±5.7% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution12/20 pts (-8 pt drag)

Cannibal Buyback (-1.24% YoY Shares) & executive Form 4 sales trim 8 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
58
Grade C$76.37+4.4% Next Q
Q2 (-2Q)
61
Grade C$79.71+0.8% Next Q
Q3 (-1Q)
63
Grade C+$80.38-0.2% Next Q
Current
66
Grade C+$80.21+1.4% Hist 90D α
Trajectory: C (58) → C+ (66)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the LIVN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 66/100 (C+) score, LIVN faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 65.2% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($78.56) or 200D SMA ($73.07) invalidates the momentum regime and cuts Target Base ($83.10) toward Bear Floor ($64.82).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LIVN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LIVN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 66%NO 34%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why LIVN Stock advanced +1.57% Today — RQD Quant Desk Flash

LivaNova PLC (LIVN) advanced +1.57% to $80.21, trading at 85% of its 52-week range ($48.82 – $85.76). Solid 67.7% gross margin (17% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.

  • ▸Technical Tape: Trading at 85% of its 52-week range ($48.82 – $85.76) with RSI-14 at 50.1 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±5.7% around $80.21 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable C+ (Hold) backed by 67.7% gross margin and $173.3M annual free cash flow.
Live LIVN Headlines & Catalysts
MARKET WIREYahoo Finance • 1d ago
LivaNova PLC (LIVN) Stock Forecasts

Yahoo Finance report covering LivaNova PLC (LIVN) market action, institutional positioning, and fundamental catalysts.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (LIVN Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LIVN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +35.79%📐 HORIZONTAL RANGE
2026-11-03O $81.25H $81.25L $78.97C $80.21VOL 575.6K
RES: $82.84SUP: $74.05SMA50: $78.56SMA200: $73.07
$87.81$79.31$70.81$62.30$53.80RES $82.84SUP $74.05$80.212026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LIVN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LIVN Butterfly Map → + Track LIVN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
13.0%/yr Implied 5Y Growth

vs. +10.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LIVN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LIVN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LIVN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LIVN)

Health Care Rank #111 of 1015 ⚔️ ITGR vs LIVN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LIVN vs. ITGR, AXGN, TMDX, CNMD)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, LivaNova PLC (LIVN) ranks #111 by composite RQD confidence (66/100, grade C+) and #170 by equity capitalization ($4.35B). Within this direct 5-issuer industry benchmark cohort, TMDX leads on earnings valuation at 12.2x trailing P/E, while TMDX leads on capital efficiency and profitability with 18.1% ROIC and 59.9% gross margin. ITGR currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with LIVN at 66/100 (C+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LIVN ACTIVE
LivaNova PLC
C+ 66/100 — 67.7% 17.3% +1.57% $4.35B Benchmark Subject
ITGR
Integer Holdings Corporation
C+ 67/100 41.8x 27.0% 6.0% -0.03% $4.30B /itgr-vs-livn →
AXGN
Axogen Inc.
D+ 53/100 — 74.3% -2.6% +0.97% $2.95B /axgn-vs-livn →
TMDX
TransMedics Group Inc.
C- 61/100 12.2x 59.9% 18.1% +1.03% $2.29B /tmdx-vs-livn →
CNMD
CONMED Corporation
C 62/100 28.9x 54.6% 7.8% +5.19% $1.32B /cnmd-vs-livn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001639691 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), LivaNova PLC (LIVN) reported GAAP revenue of $1.39B (+10.7% vs. FY2024 revenue of $1.25B , and +20.3% cumulative change since FY2023) , GAAP net income of -$242.5M, operating cash flow of $254.3M, and free cash flow of $173.3M (+27.5% YoY). On the balance sheet, LIVN closed FY2025 with $2.61B in total assets against $345.2M in total debt (Altman Z-Score: 2.21, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.39B -$242.5M $254.3M $173.3M $2.61B $345.2M
FY2024 (FY) 2024-12-31 $1.25B $63.2M $183.0M $135.9M $2.51B $549.6M
FY2023 (FY) 2023-12-31 $1.15B $17.6M $74.9M $74.9M — —

3. LIVN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LIVN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, LivaNova PLC (NASDAQ: LIVN) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 66/100 at a spot price of $80.21 (+1.57% 1D, market cap $4.35B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, LIVN ranks #111 in composite RQD confidence.

How does LIVN compare to ITGR and AXGN in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), LIVN carries a Roarable C+ (66/100 RQD), trailing P/E of N/A, gross margin of 67.7%, and ROIC of 17.3%. By comparison, ITGR (Integer Holdings Corporation) holds a C+ grade (67/100 RQD, P/E 41.8x, ROIC 6.0%, cap $4.30B) and AXGN (Axogen Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC -2.6%, cap $2.95B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LIVN?

Per LIVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001639691), LivaNova PLC generated $1.39B in revenue (+10.7% YoY), -$242.5M in net income, and $173.3M in free cash flow against $2.61B in total assets and $345.2M in total debt. Key quantitative strengths: Strong cash generator (67.7% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LIVN trading relative to its 50-day, 200-day, and 52-week technical levels?

LIVN last traded at $80.21 (+1.57% on volume of 605,561 shares), positioning the stock +2.10% above its 50-day simple moving average ($78.56) and +9.77% above its 200-day simple moving average ($73.07). Across its 52-week range of $48.82 to $85.76, LIVN sits at the 85.0% percentile with a 14-day RSI of 50.1 (NEUTRAL RANGE) and an implied next-earnings move of ±5.7% ($75.64 to $84.78).

Direct Sub-Reports: LIVN RQD Cockpit LIVN 12M Forecast LIVN Earnings & Move LIVN Dividends & DRIP LIVN Insiders & 13F LIVN Whale Options LIVN Profit Sankey LIVN News & Why
ROARABLE RATING BRIEF • RQD 66/100 (C+) ✓ SEC XBRL & RQD VERIFIED

LIVN — LivaNova PLC: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

LivaNova PLC (LIVN) earns a live Roarable RQD composite score of 66/100, corresponding to a C+ letter grade (Roarable Hold) at a spot price of $80.21 (+1.57% 1D, market capitalization $4.35B).

  • Fundamental Cash Engine (16/20): Anchored by return on invested capital (ROIC) of 17.3%, gross margin of 67.7%, operating margin of 14.4%, and free cash flow yield of 3.87%.
  • Whale 13F & Options Flow (13/20) + Insider Conviction (12/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (13/20) + Forensic Balance Sheet (12/20): Incorporates a 1.00x equity beta, Altman Z-Score of 2.21, Piotroski F-Score of 7/9, and Debt/Equity of 0.29x.

2. Business Model, Unit Margins & SEC Financial Trajectory

LivaNova PLC is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. The profile describes it as a market capitalization of $4.5B issuer. Products, customer segments, and revenue mechanics are not itemized in the source data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), LivaNova PLC (LIVN) reported $1.39B in annual revenue (up from $1.25B in FY2024, +10.7% YoY) and -$242.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.15B revenue, $17.6M net income) through FY2025, LIVN scaled operating cash flow to $254.3M and free cash flow to $173.3M, backed by $2.61B in total assets against $345.2M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C+ • RQD 66/100): Strong cash generator (67.7% gross margin)—profits are backed by real money, not accounting tricks. Free cash flow yield of 3.87% and institutional whale pillar of 13/20. With Fundamental Cash Engine at 16/20 and Institutional Whale Flow at 13/20, sustained execution supports upside toward the upper end of the $48.82 – $85.76 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Investors must weigh current valuation and 15.6x EV/EBITDA against 14.4% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

A prospective investor should note that 2nd-order ripple effects cannot be mapped from the provided material; the clinical-data theme in the news flow is the only sector-level thread visible.

  • Key Question #1: Can LIVN sustain or expand its 14.4% operating margin and 17.3% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.39B and free cash flow of $173.3M, how will capital allocation balance growth reinvestment against $345.2M in total debt?
  • Key Question #3: How sensitive is LIVN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

LIVN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for LivaNova PLC (LIVN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LIVN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LIVN Bull vs. Bear Conversation Board — What's Your Call at $80.21?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LIVN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on LIVN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $95.55 (+21.0%)
📌 Pinned Debate

ROIC of 17.3% and an FCF yield of 3.87% show a cash engine that the RQD rating scores at 16 of 20.

ROIC of 17.3% and an FCF yield of 3.87% show a cash engine that the RQD rating scores at 16 of 20.. When you look under the hood at LIVN, Fundamental Cash Engine is 16/20 with 67.7% gross margins and 17.3% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (13/20) has been quietly accumulating below $85.76. My 12M target is $95.55.

ArenaChamp_24 🐂 BULL

@ForensicBear Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Electromedical & Electrotherapeutic Apparatus. If gross margin (67.7%) holds, EPS grows into the multiple faster than bears think.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $67.91 (-14.0%)
Spot @ $78.97

A FY 2025 net loss of -$242.5M despite $199.4M of operating income, with no analyst or holder data to corroborate the rating.

Careful chasing LIVN at $78.97. A FY 2025 net loss of -$242.5M despite $199.4M of operating income, with no analyst or holder data to corroborate the rating.. Gross margin is 67.7%, but operating margin is 14.4%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $67.91 on multiple compression.

LIVE TAPE